Ok tinker bell?
I'm not lying
If GLD lends, the borrower must sell the gold to make a profit
You keep on dodging my challenge
You can't explain how a borrower can make money without selling
You must give in to the dark side
Bah ha ha ha ha
How should you start a trial Micro, when you have not received any guidance from the FDA regarding our 48 week data, and how to proceed? Are you supposed to guess, and hope you guess right? Seriously? That's basically what you are suggesting. The truth is, they had to wait for the FDA to give guidance on how to move forward. To suggest otherwise, is ridiculous. Then you'd be squawking about how CG wasted resources starting a P3 that wasn't designed the way the FDA finally decided it should be.
Your criticism is unfair, and just plain wrong as far as I'm concerned. You move forward with a large P3 once the FDA give guidance, and not until that happens. It's not SRPT's fault it took two years. It's the FDA's. Blame the right entity.
GILD will have an AWESOME Q3 and will blow OUT the minds of the Analysts AGAIN!
Let's put out the facts:
1. GILD had an awesome Q1 and Q2 results because of their blockbuster medication SOVALDI.
2. With REFILLS from Q1/Q2 + NEW patients from Q3.. GILD will generate HIGHER revenue then previous quarters.
3. Doctors are warehousing their hepatitis C patients for the new COMBINATION drug in October.
---- This combination makes it more difficult for competitors (ABBV, BMS, ETC) to compete against GILEAD.
GILEAD will DOMINATE Q3 and Q4.
Conclusion: GILD's SP will continue to rise into late October/November ---- Price Target of $125.
Sentiment: Strong Buy
I am still here just listening to you repeat yourself everyday wow you are really into me aren't you must have hit a nerve.
If you are a cancer patient, you'd rather have stable disease than progressive disease. Nobody cares that you demand only PRs.
Furthermore, there is plenty of potential profit to be had for use as a combination therapy. For example, the response rate and the disease control rate were roughly double what one expects from the chemo alone in the REO-021 sqamous cell carcinoma to the lung. It doesn't matter that only half of the treatment benefit was from Reolysin and half of the treatment benefit was from the combination chemotherapy, especially since a very small proportion of the side effects are from Reolysin! To put matters in perspective, Docetaxel was a $3B/year drug before the IP ran out, despite nasty side effects. This company only needs a tiny fraction of such profits to be worth considerably more that the present market cap of roughly $68 M.
Furthermore, REO-018 showed that this drug has a statistically significant tumor shrinkage in head & neck, which could well be used in the pre-surgical setting. Additionally, a statistically significant doubling of PFS was obtained in the worse-performing local regional group. Either of these facts alone makes the current bargain basement market valuation of the company highly suspect.
If you don't like the company then fine, but given
1) 5 externally-sponsored randomized trials yet to report,
2) the proven tumor shrinkage and PFS data from REO-018,
3) the excellent response data from REO-021,
4) and the possibility of a registration trial in some jurisdiction for neoadjuvant use
5) The likelihood that oncolytic viruses will be of general use in priming the immune system for checkpoint inhibitors.
alone, this company is just too risky for you to short. You could easily get caught holding the bag in the near term if REO-021 releases some good OS data or if regulators in the US or EU allow a favorable neoadjuvant or PFS endpoint in a registration trial.
Sentiment: Strong Buy
Shut down those polluting rare earth production outside or inside China is the best thing to do for the rare earth industry and environment.
I think it's highly possible Apple requests Sony to provide the PicoP modules for its high volume iphone7 next year. Considering the timing stated as "early production needs" in Q4 2014. From my past experience, it matches the timing for one of the key components for iphone6 which also started early production in Q4 2013.
Sentiment: Strong Buy
Define manipulation and then tell me how you think this stock is being manipulated.
and do NOT forget, Alibaba is loaded with management that is from the communist party... alibaba is the ONLY ecommerce monopoly in china... the PRC will not allow any company to compete against it.... its the only game in china becasue it has the sole backing of the PRC.... how do you think that business model is goingto work in europe and USA??